Welcome to our dedicated page for MMEDF news (Ticker: MMEDF), a resource for investors and traders seeking the latest updates and insights on MMEDF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MMEDF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MMEDF's position in the market.
MindMed has announced a leadership restructuring to strengthen its focus on integrating psychedelic drug development with digital therapeutics. J.R. Rahn will serve as the sole CEO, while Perry Dellelce has been appointed Chair. Stephen Hurst retires from co-CEO and Executive Chair roles but stays on the board, and Stanley Glick also retires from the board. The company is expanding its digital medicine division and aims to enhance its clinical trial pipeline with recent hires, including Robert Barrow as Chief Development Officer.
MindMed (OTCQB: MMEDF) has announced a $5 million funding commitment to establish a Psychedelic Medicine Research Training Program at NYU Langone Health. This initiative aims to recruit and train psychiatrists and clinical researchers in psychedelic-assisted therapies, notably for substance use disorders. The program is part of a broader plan to create a Center for Psychedelic Medicine. MindMed's partnership with NYU aligns with its ongoing research and prepares for future clinical trials, including Phase 2 trials for its ibogaine-derived molecule 18-MC for opioid use disorder.
Mind Medicine (MindMed) Inc. has partnered with University Hospital Basel's Liechti Lab to conduct research on the effects of psilocybin and LSD. This study aims to compare their impacts on altered states of consciousness, potentially aiding in the design of future psychedelic-assisted therapies. MindMed retains exclusive rights to all intellectual property derived from the research. The study is expected to conclude by Q2 2021, highlighting the growing interest in these substances for treating mental health issues.
Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF) announced that its management is unaware of any material changes that might account for increased market activity, as requested by IIROC on behalf of the NEO Exchange. The company focuses on developing psychedelic-inspired medicines aimed at improving mental health and wellness. MindMed is engaged in human clinical trials to address mental health issues such as substance use disorders. The company emphasized that their operations remain stable amidst market fluctuations.
Mind Medicine (MindMed) Inc. is pursuing a NASDAQ Capital Market up-listing to expand its investor base in the United States. An application for listing its subordinate voting shares has been submitted, pending regulatory review and acceptance by NASDAQ. The company has engaged Canaccord Genuity as a financial advisor to assess this potential up-listing and explore M&A opportunities. Co-Founder and Co-CEO JR Rahn highlighted the rapid growth of the psychedelic medicine industry as a motivating factor for this strategic move.
MindMed is initiating a Phase 1 Clinical Trial in collaboration with the University Hospital Basel Liechti Lab, combining MDMA and LSD. The trial, set to begin in Q4 2020 in Basel, Switzerland, explores the potential of combined treatments to enhance psychedelic therapy outcomes. MDMA may mitigate negative side effects of LSD, promoting a more positive experience. Dr. Matthias Liechti highlighted the trial’s aim to achieve lasting therapeutic effects through this innovative treatment. The one-year trial duration could lead to further studies based on promising results.